MediWound (MDWD) Corporate presentation summary

Company highlights and financial position

• Multibillion-dollar commercial opportunity with validated enzymatic technology platform and strategic global collaborations.

• NexoBrid generated $17M revenue in 2025; EscharEx targets a $2.5B+ U.S. market.

• Solid balance sheet with $45M cash and no debt as of March 31, 2026; runway through profitability.

• Expanded sterile manufacturing facility increases capacity sixfold, with regulatory approvals expected in 2026.

• Over $120M received from BARDA and $18M from Dow for product development and procurement.

Core technology and product portfolio

• Proprietary enzymatic biologics platform enables rapid, selective, non-surgical removal of non-viable tissue.

• NexoBrid is a disruptive therapy for burn care, approved in 40+ countries, and used in over 16,000 patients.

• EscharEx is an investigational next-generation therapy for chronic wounds, with ongoing Phase 3 trials.

• NexoBrid targets a $300M U.S. market for eschar removal in burns; EscharEx targets chronic wounds including VLU, DFU, and PU.

• Multiple strategic collaborations with leading global healthcare companies and government agencies.

Clinical data and product efficacy

• NexoBrid demonstrated superiority over standard of care (SOC) in Phase 3 trials, with higher rates of complete eschar removal, reduced need for surgery, and less blood loss.

• EscharEx showed robust and consistent results in three Phase 2 studies, achieving rapid debridement and wound bed preparation.

• Head-to-head data show EscharEx outperforms SANTYL in debridement efficacy and time to wound closure.

• EscharEx is safe, well-tolerated, and reduces bacterial burden and biofilm in chronic wounds.

• U.S. key opinion leaders support non-invasive, enzymatic debridement as a first-line approach.